Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Guangzhou Xinji Pharmaceutical Technology

Request full access

Pharmaceutical company specialising in innovative drug preparations and research

Guangzhou, ChinaBiotech & Life Sciences

About Guangzhou Xinji Pharmaceutical Technology

Guangzhou Xinji Pharmaceutical Technology Co., Ltd., operating under the name Novaken, was established in 2007 as a specialized pharmaceutical contract research organization (CRO). The company was founded by Dr. Wu Chuanbin, who serves as the Chief Scientist. Dr. Wu possesses an extensive background in pharmaceutics, holding a Ph.D. from the University of Texas at Austin and having occupied senior research and development roles at major international pharmaceutical firms such as Johnson & Johnson, Novartis, and Actavis. His industrial experience is complemented by a distinguished academic career, including being the first Chinese scientist named a Fellow of the American Association of Pharmaceutical Scientists (AAPS) and serving as a committee member for the National Pharmacopoeia.

The firm's business model is twofold, encompassing both contract research services and proprietary product development. The Pharmaceutical Contract Research Organization (PCRO) arm delivers a comprehensive suite of services to other pharmaceutical companies, including pre-formulation studies, process development, quality research, and regulatory support for FDA and EU submissions. This division aids clients in areas like generic drug consistency evaluation and new drug Chemistry, Manufacturing, and Controls (CMC) research. Novaken has established collaborations with numerous well-known domestic pharmaceutical enterprises, such as Zhuhai United Laboratories, Guangzhou Baiyunshan Pharmaceutical, and CR Sanjiu.

Concurrently, the company pursues a Pharmaceutical Product and Process Research & a-lOut-licensing (PPRO) model, focusing on the development and subsequent licensing of high-barrier formulation products. Central to this strategy are several core technology platforms, including sustained and controlled-release formulations, solubilization of poorly soluble drugs, and inhalation drug delivery systems. A key area of expertise is its microneedle technology for transdermal drug delivery. The company has developed a proprietary automated production system for creating soluble microneedle chips, which can deliver peptides, proteins, vaccines, and small molecules through the skin, aiming to improve patient compliance by offering a painless alternative to injections. This technology has applications in both pharmaceuticals and medical aesthetics. Recent milestones include receiving clinical trial approval in 2024 for a dexmedetomidine microneedle patch for pediatric sedation and a nasal spray for Parkinson's disease, with commercial launch anticipated for both around 2026.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Biotech and Pharma, DT and LS
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES C✓Equity / VC Feb 2025 $14M $55M Jinke Entertainment Culture · Gree Electric Appliance · Gree Gold Investment ↗
DEBT✓Debt Dec 2021 $14M — Danlu Capital ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Guangzhou Xinji Pharmaceutical Technology website traffic

Latest recorded traffic for Guangzhou Xinji Pharmaceutical Technology is 530 monthly website visits, up 17.8% over the last three months.

Latest monthly visits530 3-month web change+17.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Guangzhou Xinji Pharmaceutical Technology in the Guangzhou ecosystem

Live from Dealroom

The Guangzhou Xinji Pharmaceutical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later4 investors entered at this stage

  • Danlu Capital
  • Jinke Entertainment Culture
  • Gree Electric Appliance
  • Gree Gold Investment
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Guangzhou HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Guangzhou Xinji Pharmaceutical Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Guangzhou Xinji Pharmaceutical Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.